Περίληψη:
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. It is principally associated with liver cirrhosis and chronic liver disease. The major risk factors for the development of HCC include viral infections (HBV, HCV), alcoholic liver disease (ALD,) and non-alcoholic fatty liver disease (NAFLD). The optimal treatment choice is dictated by multiple variables such as tumor burden, liver function, and patient’s health status. Surgical resection, transplanta-tion, ablation, transarterial chemoembolization (TACE), and systemic therapy are potentially useful treatment strategies. TACE is considered the first-line treatment for patients with intermediate stage HCC. The purpose of this review was to assess the indications, the optimal treatment schedule, the technical factors associated with TACE, and the overall application of TACE as a personalized treatment for HCC. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Kotsifa, E.
Vergadis, C.
Vailas, M.
Machairas, N.
Kykalos, S.
Damaskos, C.
Garmpis, N.
Lianos, G.D.
Schizas, D.
